KSI-601

KSI-601 is a preclinical-stage, single molecule "triplet" biopolymer conjugate developed by Kodiak Sciences for the treatment of dry age-related macular degeneration (dry AMD)[3][4][7]. It represents a next-generation therapy from Kodiak’s Antibody Biopolymer Conjugate (ABC) platform, designed to target high-prevalence, multifactorial eye diseases by combining three biologically active moieties in a single conjugate—typically integrating a biologic and small molecule(s). KSI-601 is engineered as an intravitreal agent intended to address multiple pathogenic pathways simultaneously, though the precise molecular targets and their roles in the triplet construct have not been publicly detailed as of the latest disclosures[1][3][5][7][9]. KSI-601 is not yet approved for use and remains under preclinical investigation[7][3][4].

Other names

KSI 601KSI601KSI-601